Milk Thistle

Silymarin and silybin, the active flavolignans in Milk Thistle, inhibit CYP2C9 in vitro, the enzyme responsible for S-warfarin metabolism. Additionally, Milk Thistle may inhibit UGT enzymes involved in glucuronidation of warfarin metabolites. While clinical PK studies show modest effects, inhibition of CYP2C9 could reduce warfarin clearance and elevate INR.

Monitor INR more frequently when initiating or discontinuing Milk Thistle supplements alongside warfarin. Standard hepatoprotective doses (140-420mg silymarin/day) have shown limited clinical effect in healthy volunteers, but caution is warranted in patients with impaired hepatic function or on multiple CYP2C9 substrates.

A randomized crossover study found that high-dose Milk Thistle (300mg tid × 3 weeks) did not significantly alter indinavir pharmacokinetics in HIV+ patients on stable antiretroviral therapy, but a potential for interaction exists via CYP3A4 at very high doses. P-gp interactions are also a theoretical concern. Vigilance is warranted given the narrow TI of antiretrovirals.

While the Piscitelli 2002 clinical study showed no significant interaction at standard doses, advise HIV patients to inform their specialist before using Milk Thistle supplements. Use the lowest effective Milk Thistle dose and monitor for changes in HIV viral load and CD4 count.

In vitro and some in vivo data suggest that Milk Thistle may increase the clearance of metronidazole, possibly via induction or competition for glucuronidation. The clinical significance is unclear, but sub-therapeutic metronidazole levels during treatment for Clostridium difficile, bacterial vaginosis, or parasitic infections could compromise efficacy.

Avoid high-dose Milk Thistle concurrently with metronidazole treatment courses. If co-administration is unavoidable, monitor clinical response to metronidazole therapy. Resume Milk Thistle after completion of the antibiotic course.

Raloxifene is extensively glucuronidated by UGT1A1 and UGT1A8. Silybin inhibits UGT-mediated glucuronidation, as demonstrated in clinical studies measuring raloxifene glucuronide:raloxifene ratios. Reduced glucuronidation increases raloxifene plasma concentrations, potentially intensifying both beneficial (bone protection) and adverse effects (hot flashes, thromboembolism risk).

Monitor for increased raloxifene adverse effects (hot flushes, leg cramps) in women taking both. Assess VTE risk, particularly in patients with additional risk factors. Inform patients about this interaction as Milk Thistle is commonly used by women with cancer risk concerns who may also be on raloxifene.

Silybin and other Milk Thistle flavolignans inhibit CYP2B6 in vitro and in clinical studies. CYP2B6 substrates include bupropion (antidepressant/smoking cessation), cyclophosphamide (prodrug requiring CYP2B6 activation), and efavirenz (NNRTI HIV medication). CYP2B6 inhibition increases bupropion and efavirenz plasma levels; for cyclophosphamide, inhibition may reduce activation to its cytotoxic metabolites.

Exercise caution with Milk Thistle in patients on bupropion (monitor for seizure threshold lowering, hypertension), efavirenz (monitor for CNS side effects and virological response), or cyclophosphamide chemotherapy (may alter efficacy). Consider dose adjustment of CYP2B6 substrates.

Silymarin flavonolignans inhibit UDP-glucuronosyltransferase (UGT1A1) enzyme activity responsible for glucuronidation of the active irinotecan metabolite SN-38. UGT inhibition reduces inactivation of SN-38, potentially increasing systemic exposure of this toxic metabolite, with risk of severe diarrhea and neutropenia.

Avoid milk thistle supplementation during irinotecan-based chemotherapy regimens (FOLFIRI, XELIRI). If concurrent use cannot be avoided, monitor closely for hallmark irinotecan toxicities: grade ≥3 diarrhea and neutropenia. Report any unexpected toxicity to the oncology team promptly.

Silymarin inhibits OATP1B1 hepatic uptake transporters and exhibits modest P-glycoprotein inhibitory activity, leading to increased systemic exposure of rosuvastatin. A clinical pharmacokinetic study found a statistically significant increase in rosuvastatin AUC and Cmax following 5-day co-administration with silymarin.

Clinically significant interaction is unlikely at standard silymarin doses (140-420 mg/day). However, use the lowest effective rosuvastatin dose when combined with high-dose milk thistle. Monitor for statin myopathy (muscle pain, weakness, elevated creatine kinase) in patients on concurrent therapy.

A clinical study found that 14-day silymarin administration produced a modest but statistically significant increase in oral talinolol AUC and Cmax, consistent with P-glycoprotein (ABCB1) inhibition by silymarin constituents in the intestinal wall. Talinolol is a validated P-gp probe substrate.

Clinically significant interaction at standard milk thistle doses is unlikely for most patients. For P-gp substrates with narrow therapeutic indices (digoxin, some immunosuppressants), monitor drug levels if high-dose silymarin is added. No dose adjustment routinely required for beta-blockers.

In vitro, silymarin components (isosilybin B, silychristin) significantly inhibit CYP3A4 at concentrations above 50-100 μM; additionally, silymarin inhibits UGT-mediated glucuronidation. Both pathways are involved in tacrolimus metabolism. At high silymarin doses in transplant patients, these interactions could elevate tacrolimus trough levels and precipitate nephrotoxicity.

Transplant patients on tacrolimus should avoid high-dose milk thistle. If used, employ the lowest effective silymarin dose and monitor tacrolimus trough levels regularly. Any unexplained fluctuation in tacrolimus levels should prompt review of concurrent herbal supplement use. Report nephrotoxicity or neurotoxicity symptoms immediately.

Silymarin has demonstrated insulin-sensitising and glucose-lowering properties in multiple RCTs involving patients with type 2 diabetes and diabetic nephropathy, likely via antioxidant effects on pancreatic beta cells and improved insulin receptor signalling. Additive pharmacodynamic reduction in blood glucose is possible.

Monitor blood glucose levels when adding or stopping milk thistle in diabetic patients. The interaction may be beneficial (improved glycaemic control) but could theoretically increase hypoglycaemia risk if antidiabetic doses are not adjusted. No routine dose adjustment is required but patient education about hypoglycaemia symptoms is advised.

Silymarin (the primary flavonolignan in milk thistle) potently inhibits organic anion-transporting polypeptides OATP1B1, OATP1B3, and OATP2B1 in vitro. These hepatic uptake transporters are critical for statin (especially rosuvastatin and pravastatin) disposition. Inhibition of OATP1B1/1B3 reduces hepatic statin uptake, increasing systemic statin plasma concentrations and raising the risk of statin-associated myopathy and rhabdomyolysis. A clinical study showed milk thistle increased rosuvastatin AUC.

Avoid concurrent use of high-dose milk thistle with statins primarily cleared by OATP transporters (rosuvastatin, pravastatin, atorvastatin). If co-administration is necessary, use the lowest effective statin dose and monitor for myopathy (muscle pain, weakness, elevated CK). Patients should immediately report severe muscle pain or brown discoloration of urine (myoglobinuria).

Silymarin inhibits UGT (UDP-glucuronosyltransferase) enzymes including UGT1A1, UGT1A6, UGT1A9, and UGT2B7 in human hepatocyte cultures. Acetaminophen undergoes significant glucuronidation (40-67% of dose) via UGT1A1, UGT1A6, and UGT2B15. Inhibition of these UGTs may reduce acetaminophen glucuronidation, shifting metabolism toward the potentially toxic CYP2E1-mediated NAPQI pathway. However, at standard milk thistle doses, silybin plasma concentrations are likely too low to cause clinically significant UGT inhibition in vivo.

At standard doses of milk thistle (175-420 mg silymarin/day) the interaction with acetaminophen is likely theoretical. However, patients taking high-dose milk thistle should be cautioned against exceeding recommended acetaminophen doses and should avoid concurrent alcohol (which also induces CYP2E1). The hepatoprotective properties of milk thistle may paradoxically reduce acetaminophen-induced liver injury.

Silymarin has demonstrated insulin-sensitizing and glucose-lowering effects in clinical studies of patients with type 2 diabetes and liver disease. Mechanisms include reduced oxidative stress-mediated beta cell damage, improved insulin receptor sensitivity, and decreased hepatic glucose output. Combined use with antidiabetic agents (especially insulin and sulfonylureas) may produce additive blood glucose lowering and increase the risk of hypoglycemia.

Patients with diabetes who use milk thistle should monitor blood glucose regularly, especially during the first month. Alert clinicians to the potential for lower antidiabetic medication requirements. Advise patients to report symptoms of hypoglycemia. Some practitioners intentionally combine milk thistle with metformin in diabetic liver disease patients, with physician oversight.